Immunovant Stock Performance
| IMVT Stock | USD 26.45 0.39 1.50% |
Immunovant has a performance score of 4 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 0.41, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Immunovant's returns are expected to increase less than the market. However, during the bear market, the loss of holding Immunovant is expected to be smaller as well. Immunovant right now retains a risk of 2.6%. Please check out Immunovant maximum drawdown, as well as the relationship between the skewness and day typical price , to decide if Immunovant will be following its current trending patterns.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Immunovant are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating basic indicators, Immunovant may actually be approaching a critical reversion point that can send shares even higher in March 2026. ...more
| Begin Period Cash Flow | 635.4 M | |
| Total Cashflows From Investing Activities | -759 K | |
| Free Cash Flow | -376.6 M |
Immunovant | Build AI portfolio with Immunovant Stock |
Immunovant Relative Risk vs. Return Landscape
If you would invest 2,468 in Immunovant on October 31, 2025 and sell it today you would earn a total of 177.00 from holding Immunovant or generate 7.17% return on investment over 90 days. Immunovant is currently generating 0.1468% in daily expected returns and assumes 2.599% risk (volatility on return distribution) over the 90 days horizon. In different words, 23% of stocks are less volatile than Immunovant, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Immunovant Target Price Odds to finish over Current Price
The tendency of Immunovant Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 26.45 | 90 days | 26.45 | about 16.02 |
Based on a normal probability distribution, the odds of Immunovant to move above the current price in 90 days from now is about 16.02 (This Immunovant probability density function shows the probability of Immunovant Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Immunovant has a beta of 0.41. This usually indicates as returns on the market go up, Immunovant average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Immunovant will be expected to be much smaller as well. Additionally Immunovant has an alpha of 0.1156, implying that it can generate a 0.12 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Immunovant Price Density |
| Price |
Predictive Modules for Immunovant
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Immunovant. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Immunovant's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Immunovant Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Immunovant is not an exception. The market had few large corrections towards the Immunovant's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Immunovant, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Immunovant within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.12 | |
β | Beta against Dow Jones | 0.41 | |
σ | Overall volatility | 1.56 | |
Ir | Information ratio | 0.03 |
Immunovant Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Immunovant for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Immunovant can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Immunovant has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (413.84 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Immunovant currently holds about 427.2 M in cash with (375.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.66. | |
| Roughly 57.0% of the company shares are held by company insiders |
Immunovant Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Immunovant Stock often depends not only on the future outlook of the current and potential Immunovant's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Immunovant's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 151.6 M | |
| Cash And Short Term Investments | 714 M |
Immunovant Fundamentals Growth
Immunovant Stock prices reflect investors' perceptions of the future prospects and financial health of Immunovant, and Immunovant fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Immunovant Stock performance.
| Return On Equity | -0.96 | |||
| Return On Asset | -0.55 | |||
| Current Valuation | 4.54 B | |||
| Shares Outstanding | 201.48 M | |||
| Price To Book | 10.10 X | |||
| EBITDA | (437.77 M) | |||
| Cash And Equivalents | 427.2 M | |||
| Cash Per Share | 3.66 X | |||
| Total Debt | 98 K | |||
| Debt To Equity | 0 % | |||
| Book Value Per Share | 2.98 X | |||
| Cash Flow From Operations | (375.87 M) | |||
| Earnings Per Share | (2.82) X | |||
| Total Asset | 776.22 M | |||
| Retained Earnings | (1.24 B) | |||
About Immunovant Performance
Assessing Immunovant's fundamental ratios provides investors with valuable insights into Immunovant's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Immunovant is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 124 people.Things to note about Immunovant performance evaluation
Checking the ongoing alerts about Immunovant for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Immunovant help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Immunovant has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (413.84 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Immunovant currently holds about 427.2 M in cash with (375.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.66. | |
| Roughly 57.0% of the company shares are held by company insiders |
- Analyzing Immunovant's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Immunovant's stock is overvalued or undervalued compared to its peers.
- Examining Immunovant's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Immunovant's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Immunovant's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Immunovant's stock. These opinions can provide insight into Immunovant's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Immunovant Stock Analysis
When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.